

# Cellmid Ltd

12:39 01 Nov 2018

## Cellmid launches évolis® Professional products in 17 store locations across the US

Cellmid Ltd (ASX:CDY) has successfully completed the initial 17-store launch in the US for its anti-aging hair care range, évolis® Professional.

As a result of the strong response during these launch events, all three retail partners (Bloomingdales, Neiman Marcus and Soft Surroundings) have advised on additional store locations for the products.

**READ:** Cellmid set to launch its anti-aging hair care range in major stores across the U.S.

Bloomingdales will stock évolis® Professional in eight additional stores from January 2019, taking the total store presence to nine flagship locations, representing about 2.5% of the total store numbers within the Macy's Group (NYSE:M).

Cellmid will be given five additional Neiman Marcus store placements from March 2019 and a further 10 store placements from September 2019, taking the total number of Neiman Marcus doors to 20 by late 2019, representing around 30% of the total number of stores within the group.

Following the strong in-store performance, a further 10 Soft Surroundings stores will range the évolis® Professional products from early 2019, taking the total number of doors to 21, representing about 20% of the total number of stores within the group.

**READ:** Cellmid driving towards profitability with anti-ageing product range

With a substantial increase in store locations across the US, Cellmid is now focused on implementing a cost-effective experiential marketing solution.

The company has signed an agreement with a US retail specialist providing local brand ambassadors on a contract basis from the end of November 2018.

Cellmid CEO Maria Halasz said: "Our US team, led by Colour Collective's managing director Kerry Yates, has done an exceptional job during the launch events

"The results confirm our differentiated launch strategy and give us confidence to continue to scale into this lucrative distribution channel using a professional, cost effective, local retail team"

Early repayment of R&D loan

Cellmid has repaid the remaining \$1 million of the \$2 million R&D loan facility provided to it by Platinum Road in February 2017.

**Price:** A\$0.205

**Market Cap:** A\$17.14M

### 1 Year Share Price Graph



### Share Information

**Code:** CDY

**Listing:** ASX

**52 week High Low**  
A\$0.47 A\$0.17

**Sector:** Pharma & Biotech

**Website:** www.cellmid.com.au

### Company Synopsis:

*Cellmid Ltd (ASX:CDY) is an Australian life sciences company with lead programs in multiple disease indications.*

**Author:**

**Proactive Investors Australia**

**+61 (0)2 9280 0700**

**action@proactiveinvestors.com.au**

By repaying the entire \$2 million of the loan before due date, Cellmid has saved a total of \$90,000 in interest.

With the recent \$10 million fundraising, \$9 million in a private placement, a further \$1 million via a share purchase plan, and the R&D tax credit received of \$808,000, Cellmid is well funded to maximise the growth potential of its business and continue on the path of improved financial performance.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.